Breast cancer is the most common cancer among women, with over 2.3 million new cases diagnosed each year. Traditional ...

Researchers developed and validated a new lung cancer prediction model, Sybil-Epi, by integrating clinical and epidemiologic data with a pre-existing model.

Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, ...

Despite major advances in genetic testing for breast cancer risk prediction, death rates remain disproportionately high among women of African ancestry. This is often due to a combination of factors, ...

A new long-term prediction tool estimates the risk of dying from prostate cancer, offering a more accurate way to interpret prostate-specific antigen (PSA) test results compared to existing models.

In this episode of eSpeaks, Jennifer Margles, Director of Product Management at BMC Software, discusses the transition from traditional job scheduling to the era of the autonomous enterprise. eSpeaks’ ...

Low-dose computed tomography (LDCT) screening is effective in reducing lung cancer mortality by detecting the disease at earlier, more treatable stages. However, high false-positive rates and the ...

Re-prompting for ESR1 mutations in breast cancer: Improving mutation reporting and therapeutic decision-making. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care Symposium. This ...

The intersection of artificial intelligence (AI) and healthcare presents a transformative frontier, particularly in the global fight against cancer. As healthcare systems worldwide grapple with rising ...

CLAIRITY BREAST provides clinicians with a first-in-class, novel platform for identifying future risk of breast cancer CLAIRITY BREAST analyzes subtle imaging features on screening mammograms that ...